Home ReViral Ltd

ReViral Ltd

ReViral Announces Grant of Key US Composition of Matter Patent for their Respiratory Syncytial Virus Inhibitor Program

4/8/19: This composition of matter patent claims certain inhibitors of the fusion protein of the respiratory syncytial virus (RSV), including RV521, the Company’s lead pipeline asset. The counterpart to this patent, EP3204375, has also been issued in Europe.